Itraconazole (PUR1900)

Small molecule

Stoppedregistry status

Evidence outlook

Phase 2 study terminated, no active studies registered

The furthest-phase study registered for this program (NCT03960606) was terminated, and no study is currently active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (1)
Allergic Bronchopulmonary Aspergillosis
Phase 1 (1)
Other / comorbidity

Competitive landscape

This drug's own stage for Allergic Bronchopulmonary Aspergillosis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Itraconazole (PUR1900): this drugPhase 2Small moleculefungal CYP51 (lanosterol 14α-demethylase)not yet gradedNo reviewed efficacy summary in this indication
Voriconazole (ZP-059)Phase 1Small moleculefungal CYP51 / lanosterol 14-alpha-demethylaseWeak signalFeatured results are safety only in this race

Upcoming events

No upcoming readouts on record for this asset.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 August 2026Topline resultCipla completed its Phase 2 of inhaled itraconazole (PUR1900) in India with positive results; India's CDSCO approved a Phase 3
Cipla · Source ↗